Abstract

BackgroundSarcomas, cancers originating from mesenchymal cells, are comprehensive tumors with poor prognoses, yet their tumorigenic mechanisms are largely unknown. In this study, we characterize infiltrating immune cells and analyze immune scores to identify the molecular mechanism of immunologic response to sarcomas.MethodThe “CIBERSORT” algorithm was used to calculate the amount of L22 immune cell infiltration in sarcomas. Then, the “ESTIMATE” algorithm was used to assess the “Estimate,” “Immune,” and “Stromal” scores. Weighted gene co-expression network analysis (WGCNA) was utilized to identify the significant module related to the immune therapeutic target. Gene ontology (GO) enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were performed using the “clusterProfiler” package in R for annotation and visualization.ResultsMacrophages were the most common immune cells infiltrating sarcomas. The number of CD8 T cells was negatively associated with that of M0 and M2 macrophages, and positively associated with M macrophages in sarcomas samples. The clinical parameters (disease type, gender) significantly increased with higher Estimate, Immune, and Stromal scores, and with a better prognosis. The blue module was significantly associated with CD8 T cells. Functional enrichment analysis showed that the blue module was mainly involved in chemokine signaling and the PI3K-Akt signaling pathway. CD48, P2RY10 and RASAL3 were identified and validated at the protein level.ConclusionBased on the immune cell infiltration and immune microenvironment, three key genes were identified, thus presenting novel molecular mechanisms of sarcoma metastasis.

Highlights

  • Sarcomas, cancers originating from mesenchymal cells, are comprehensive tumors with poor prognoses, yet their tumorigenic mechanisms are largely unknown

  • The blue module was significantly associated with CD8 T cells

  • Sarcomas are a widespread, heterogeneous group of tumors that occur on the skin, under the skin, in the periosteum, and on the ends of the long bones of adolescents and the elderly [1], which is characteristic of cancers originating from mesenchymal cells [2]

Read more

Summary

Introduction

Cancers originating from mesenchymal cells, are comprehensive tumors with poor prognoses, yet their tumorigenic mechanisms are largely unknown. We characterize infiltrating immune cells and analyze immune scores to identify the molecular mechanism of immunologic response to sarcomas. Standard of care for patients with sarcoma is mainly comprised of local surgery, chemotherapy, and radiotherapy [12]. Chemotherapy and radiotherapy are included before and after surgery to prevent recurrence [14]; the success rate of treatment is currently low, and many patients still have poor prognoses and die of cancer-related causes. With the enhanced study of the immune system, immunotherapy has emerged as very promising method to treat sarcomas after surgery and chemotherapy [16]. The characterization of sarcoma-specific biomarkers and the molecular mechanisms responsible for the transformation of normal cells to sarcoma are essential for the success of sarcoma immunotherapy

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call